CNS recurrence following CD34+ peripheral blood stem cell transplantation in stage 4 neuroblastoma.
We report here central nervous system (CNS) recurrence in neuroblastoma (NBL) after CD34(+) peripheral blood stem cell transplantation (PBSCT). Fifteen stage 4 NBL patients underwent CD34(+) transplantation with myeloablative chemotherapy consisting of carboplatin, etoposide, and melphalan. There were three primary site recurrences and five distant metastases including four brain metastases (two isolated CNS recurrences) at 4-7 months after CD34(+) transplantation. Three of four patients died of CNS progressive disease at 2, 8, and 9 months after recurrence and the remaining single patient was lost to follow-up. CNS recurrence in NBL is fatal and requires identification of risk factors and more effective treatment strategies.
Choi
Hyoung Soo
HS
Department of Pediatrics and Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-744, Korea.
Koh
Sang Hyeok
SH
Park
Eun Sil
ES
Shin
Hee Young
HY
Ahn
Hyo Seop
HS
D018952:Antigens, CD34; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000556:secondary*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D015994:Incidence; D007223:Infant; D007723:Korea / Q000453:epidemiology; D008297:Male; D009447:Neuroblastoma / Q000453:epidemiology / Q000473:pathology / Q000556:secondary* / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation; D012306:Risk
D018952:Antigens, CD34